Pub. Date : 1991
PMID : 1667418
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines. | Suramin | vasoactive intestinal peptide | Homo sapiens |
| 2 | Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines. | Suramin | vasoactive intestinal peptide | Homo sapiens |
| 3 | Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines. | Suramin | vasoactive intestinal peptide | Homo sapiens |
| 4 | The antihelminthic drug suramin inhibits the binding of monoradioiodinated VIP (125I-VIP) to two human cancerous cell lines, namely HT 29-D4 and IGR 39 derived from a colic adenocarcinoma and a superficial melanoma respectively, with an IC50 of 280 micrograms/ml. | Suramin | vasoactive intestinal peptide | Homo sapiens |
| 5 | The antihelminthic drug suramin inhibits the binding of monoradioiodinated VIP (125I-VIP) to two human cancerous cell lines, namely HT 29-D4 and IGR 39 derived from a colic adenocarcinoma and a superficial melanoma respectively, with an IC50 of 280 micrograms/ml. | Suramin | vasoactive intestinal peptide | Homo sapiens |
| 6 | Suramin at 1000 micrograms/ml inhibits by 56% to 99% the cAMP accumulation induced by VIP, depending on the VIP concentrations and the cell lines used for the experiments. | Suramin | vasoactive intestinal peptide | Homo sapiens |
| 7 | Suramin at 1000 micrograms/ml inhibits by 56% to 99% the cAMP accumulation induced by VIP, depending on the VIP concentrations and the cell lines used for the experiments. | Suramin | vasoactive intestinal peptide | Homo sapiens |